Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5378464A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Mar 8, 1989 |
| Grant date | Jan 3, 1995 |
| Priority date | — |
| Expiry date | Mar 8, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method using compounds inhibiting binding reactions involving GMP-140 to modulate an inflammatory response. The method is based on the discovery that GMP-140, released from the storage granules of platelets, endothelial cells, and megakaryocytes, and redistributed to the surface of the cells within seconds of activation by mediators such as thrombin, ionophores or histamine, binds to a ligand on neutrophils, and the plasma proteins C3b and protein S. Adhesion of the cells following activation is blocked directly by administration of antibody to GMP-140 or its ligand, or by competitive inhibition by administration of soluble GMP-140, the GMP-140 ligand, or the specific carbohydrate portion of the ligand bound by GMP-140.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.